Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 7.97
SUPN's Cash to Debt is ranked higher than
59% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. SUPN: 7.97 )
Ranked among companies with meaningful Cash to Debt only.
SUPN' s 10-Year Cash to Debt Range
Min: 0.19  Med: 2.74 Max: No Debt
Current: 7.97
Equity to Asset 0.66
SUPN's Equity to Asset is ranked higher than
54% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SUPN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
SUPN' s 10-Year Equity to Asset Range
Min: -2.25  Med: 0.33 Max: 0.68
Current: 0.66
-2.25
0.68
Interest Coverage 4.88
SUPN's Interest Coverage is ranked lower than
89% of the 389 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. SUPN: 4.88 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s 10-Year Interest Coverage Range
Min: 1  Med: 2.94 Max: 4.88
Current: 4.88
1
4.88
F-Score: 7
Z-Score: 10.90
M-Score: -1.13
WACC vs ROIC
1.00%
139.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 27.58
SUPN's Operating margin (%) is ranked higher than
91% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. SUPN: 27.58 )
Ranked among companies with meaningful Operating margin (%) only.
SUPN' s 10-Year Operating margin (%) Range
Min: -37851.89  Med: -515.18 Max: 27.1
Current: 27.58
-37851.89
27.1
Net-margin (%) 23.99
SUPN's Net-margin (%) is ranked higher than
91% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.89 vs. SUPN: 23.99 )
Ranked among companies with meaningful Net-margin (%) only.
SUPN' s 10-Year Net-margin (%) Range
Min: -36285.85  Med: -376.67 Max: 6701.74
Current: 23.99
-36285.85
6701.74
ROE (%) 47.76
SUPN's ROE (%) is ranked higher than
94% of the 696 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. SUPN: 47.76 )
Ranked among companies with meaningful ROE (%) only.
SUPN' s 10-Year ROE (%) Range
Min: -202.72  Med: -141.55 Max: 37.92
Current: 47.76
-202.72
37.92
ROA (%) 26.95
SUPN's ROA (%) is ranked higher than
94% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.32 vs. SUPN: 26.95 )
Ranked among companies with meaningful ROA (%) only.
SUPN' s 10-Year ROA (%) Range
Min: -90.03  Med: -30.02 Max: 106.84
Current: 26.95
-90.03
106.84
ROC (Joel Greenblatt) (%) 447.74
SUPN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.13 vs. SUPN: 447.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SUPN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4247.75  Med: -2739.56 Max: 1356
Current: 447.74
-4247.75
1356
Revenue Growth (3Y)(%) 68.90
SUPN's Revenue Growth (3Y)(%) is ranked higher than
97% of the 546 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SUPN: 68.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SUPN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 34.45 Max: 75.7
Current: 68.9
0
75.7
» SUPN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SUPN Guru Trades in Q3 2014

Jim Simons 36,700 sh (New)
Robert Bruce 400,000 sh (+300.00%)
Louis Moore Bacon Sold Out
» More
Q4 2014

SUPN Guru Trades in Q4 2014

Paul Tudor Jones 13,966 sh (New)
Jim Simons 157,049 sh (+327.93%)
Robert Bruce 694,581 sh (+73.65%)
» More
Q1 2015

SUPN Guru Trades in Q1 2015

George Soros 107,308 sh (New)
Joel Greenblatt 41,686 sh (New)
Paul Tudor Jones 42,987 sh (+207.80%)
Robert Bruce 694,581 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

SUPN Guru Trades in Q2 2015

Jim Simons 115,000 sh (New)
Joel Greenblatt 88,267 sh (+111.74%)
Robert Bruce 694,581 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 24,900 sh (-42.08%)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.90
SUPN's P/E(ttm) is ranked higher than
52% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SUPN: 33.90 )
Ranked among companies with meaningful P/E(ttm) only.
SUPN' s 10-Year P/E(ttm) Range
Min: 0.14  Med: 22.32 Max: 51.66
Current: 33.9
0.14
51.66
PE(NRI) 25.40
SUPN's PE(NRI) is ranked higher than
65% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.40 vs. SUPN: 25.40 )
Ranked among companies with meaningful PE(NRI) only.
SUPN' s 10-Year PE(NRI) Range
Min: 13.23  Med: 24.91 Max: 30.3
Current: 25.4
13.23
30.3
P/B 8.44
SUPN's P/B is ranked lower than
83% of the 644 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. SUPN: 8.44 )
Ranked among companies with meaningful P/B only.
SUPN' s 10-Year P/B Range
Min: 3.23  Med: 7.33 Max: 18.63
Current: 8.44
3.23
18.63
P/S 6.08
SUPN's P/S is ranked lower than
69% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.13 vs. SUPN: 6.08 )
Ranked among companies with meaningful P/S only.
SUPN' s 10-Year P/S Range
Min: 3.22  Med: 24.96 Max: 157
Current: 6.08
3.22
157
PFCF 18.94
SUPN's PFCF is ranked higher than
81% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.27 vs. SUPN: 18.94 )
Ranked among companies with meaningful PFCF only.
SUPN' s 10-Year PFCF Range
Min: 16.41  Med: 25.68 Max: 452
Current: 18.94
16.41
452
POCF 18.54
SUPN's POCF is ranked higher than
71% of the 387 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.20 vs. SUPN: 18.54 )
Ranked among companies with meaningful POCF only.
SUPN' s 10-Year POCF Range
Min: 16.07  Med: 24.69 Max: 180.8
Current: 18.54
16.07
180.8
EV-to-EBIT 20.52
SUPN's EV-to-EBIT is ranked higher than
60% of the 488 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.19 vs. SUPN: 20.52 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s 10-Year EV-to-EBIT Range
Min: -11.8  Med: -2.90 Max: 49.8
Current: 20.52
-11.8
49.8
Current Ratio 2.90
SUPN's Current Ratio is ranked higher than
61% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SUPN: 2.90 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s 10-Year Current Ratio Range
Min: 1.51  Med: 3.56 Max: 7.26
Current: 2.9
1.51
7.26
Quick Ratio 2.53
SUPN's Quick Ratio is ranked higher than
65% of the 617 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SUPN: 2.53 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s 10-Year Quick Ratio Range
Min: 1.51  Med: 3.23 Max: 7.26
Current: 2.53
1.51
7.26
Days Inventory 647.95
SUPN's Days Inventory is ranked lower than
98% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.66 vs. SUPN: 647.95 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s 10-Year Days Inventory Range
Min: 652.7  Med: 1012.71 Max: 1372.72
Current: 647.95
652.7
1372.72
Days Sales Outstanding 44.61
SUPN's Days Sales Outstanding is ranked higher than
73% of the 598 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.39 vs. SUPN: 44.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s 10-Year Days Sales Outstanding Range
Min: 2.71  Med: 72.56 Max: 16387.12
Current: 44.61
2.71
16387.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 48.11
SUPN's Price/Net Cash is ranked lower than
84% of the 178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. SUPN: 48.11 )
Ranked among companies with meaningful Price/Net Cash only.
SUPN' s 10-Year Price/Net Cash Range
Min: 4.22  Med: 28.42 Max: 62.83
Current: 48.11
4.22
62.83
Price/Net Current Asset Value 16.04
SUPN's Price/Net Current Asset Value is ranked lower than
75% of the 385 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. SUPN: 16.04 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SUPN' s 10-Year Price/Net Current Asset Value Range
Min: 3.98  Med: 11.57 Max: 42.12
Current: 16.04
3.98
42.12
Price/Tangible Book 9.52
SUPN's Price/Tangible Book is ranked lower than
80% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. SUPN: 9.52 )
Ranked among companies with meaningful Price/Tangible Book only.
SUPN' s 10-Year Price/Tangible Book Range
Min: 3.85  Med: 6.16 Max: 19.29
Current: 9.52
3.85
19.29
Price/Median PS Value 0.24
SUPN's Price/Median PS Value is ranked higher than
97% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. SUPN: 0.24 )
Ranked among companies with meaningful Price/Median PS Value only.
SUPN' s 10-Year Price/Median PS Value Range
Min: 0.13  Med: 0.84 Max: 4.98
Current: 0.24
0.13
4.98
Price/Graham Number 3.22
SUPN's Price/Graham Number is ranked lower than
58% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. SUPN: 3.22 )
Ranked among companies with meaningful Price/Graham Number only.
SUPN' s 10-Year Price/Graham Number Range
Min: 2  Med: 2.08 Max: 3.07
Current: 3.22
2
3.07
Earnings Yield (Greenblatt) (%) 4.90
SUPN's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. SUPN: 4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SUPN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2  Med: 5.60 Max: 10.6
Current: 4.9
2
10.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:S49.Germany,
Supernus Pharmaceuticals Inc was incorporated in Delaware on March 30, 2005. The Company is a specialty pharmaceutical company engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has other proprietary product candidates in clinical development that address the psychiatry market. The Company is developing multiple product candidates in psychiatry to address the unmet medical needs and market opportunities in impulsive aggression across several areas including attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder, and ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR. Oxtellar XR is indicated for adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age and Trokendi XR is indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures or with seizures associated with Lennox-Gastaut syndrome. Its psychiatry product candidates include ADHD, SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). ADHD is a common CNS disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity; and it develops SPN-810 (molindone hydrochloride) as a treatment for impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment. The Company has a portfolio of drug development technologies consisting of platforms including Microtrol, Solutrol and EnSoTrol. It is utilized to create nine marketed products, including Trokendi XR and Oxtellar XR, as well as other product candidates SPN-810 and SPN-812. The Company markets its products in the United States through its specialty sales force. The Company is subject to regulation by FDA, federal and state government authorities. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 28 2015
Supernus to Attend FBR Healthcare Conference on September 9th Aug 27 2015
Supernus to Attend FBR Healthcare Conference on September 9th Aug 27 2015
SUPERNUS PHARMACEUTICALS INC Financials Aug 20 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Aug 07 2015
Edited Transcript of SUPN earnings conference call or presentation 5-Aug-15 1:00pm GMT Aug 05 2015
Supernus Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Aug 05 2015
New ADHD drug for adults on fast-track for FDA: CEO Aug 05 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2015
Supernus Announces Second Quarter 2015 Financial Results Aug 04 2015
Supernus Announces Second Quarter 2015 Financial Results Aug 04 2015
Q2 2015 Supernus Pharmaceuticals Inc Earnings Release - After Market Close Aug 04 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2015
Supernus to Host Second Quarter 2015 Earnings Conference Call Jul 20 2015
Supernus to Host Second Quarter 2015 Earnings Conference Call Jul 20 2015
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 19 2015
Supernus Pharma upgraded by Jefferies Jun 18 2015
Supernus Corrects Earlier Statement Regarding Distribution of Common Stock by NEA Jun 17 2015
Supernus Corrects Earlier Statement Regarding Distribution of Common Stock by NEA Jun 17 2015
Supernus Announces Distribution of Common Stock by NEA Jun 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK